-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

AbbVie Says Reported GAAP Earnings, Adj. Earnings For Q4 Are Expected To Include Acquired IPR&D Milestones, Expense Of $243M On Pre-Tax Basis; Says FY22 Adj. EPS Including Impact Of Q4 Acquired IPR&D, Milestones Expense Is $13.70-$13.74 Vs $13.85 Est.

Benzinga · 01/06/2023 16:21

-SEC Filing